• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Further shuffling at Leo Pharma as dermatology drugmaker splits R&D

cafead

Administrator
Staff member
  • cafead   Mar 15, 2023 at 10:12: AM
via Danish dermatology drugmaker Leo Pharma said it will split its R&D operations into two separate teams.

The company had about 6,000 employees in early 2022 but, at the time, said it would eliminate 1,000 positions in two years. Then, this January, Leo said it would further reduce headcount by about 300 positions in a rehashing of its sourcing model to emphasize external help in finding orals, topicals and biologics. Leo now says it employs 4,700 people worldwide.

article source